PortfoliosLab logoPortfoliosLab logo
MLTX vs. ASST
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

MLTX vs. ASST - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in MoonLake Immunotherapeutics (MLTX) and Asset Entities Inc. Class B Common Stock (ASST). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, MLTX achieves a 38.62% return, which is significantly higher than ASST's -0.14% return.


MLTX

1D
2.24%
1M
4.04%
YTD
38.62%
6M
36.85%
1Y
-62.37%
3Y*
-13.16%
5Y*
12.70%
10Y*

ASST

1D
-8.56%
1M
-9.87%
YTD
-0.14%
6M
-29.81%
1Y
-89.47%
3Y*
-47.18%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

MLTX vs. ASST - Yearly Performance Comparison


2026 (YTD)202520242023
MLTX
MoonLake Immunotherapeutics
38.62%-75.66%-10.33%401.16%
ASST
Asset Entities Inc. Class B Common Stock
-0.14%50.46%-84.65%-82.00%

Correlation

The correlation between MLTX and ASST is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.16

Correlation (3Y)
Calculated over the trailing 3-year period

0.09

Correlation (All Time)
Calculated using the full available price history since Feb 6, 2023

0.07

Fundamentals

Market Cap

MLTX:

$1.30B

ASST:

$908.43M

EPS

MLTX:

-$3.90

ASST:

-$25.54

Total Revenue (TTM)

MLTX:

$0.00

ASST:

$5.73M

Gross Profit (TTM)

MLTX:

-$1.49M

ASST:

-$7.43M

EBITDA (TTM)

MLTX:

-$179.84M

ASST:

-$304.63M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

MLTX vs. ASST — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MLTX
MLTX Risk / Return Rank: 3232
Overall Rank
MLTX Sharpe Ratio Rank: 1818
Sharpe Ratio Rank
MLTX Sortino Ratio Rank: 4747
Sortino Ratio Rank
MLTX Omega Ratio Rank: 6060
Omega Ratio Rank
MLTX Calmar Ratio Rank: 1515
Calmar Ratio Rank
MLTX Martin Ratio Rank: 2121
Martin Ratio Rank

ASST
ASST Risk / Return Rank: 1313
Overall Rank
ASST Sharpe Ratio Rank: 1717
Sharpe Ratio Rank
ASST Sortino Ratio Rank: 1212
Sortino Ratio Rank
ASST Omega Ratio Rank: 1414
Omega Ratio Rank
ASST Calmar Ratio Rank: 44
Calmar Ratio Rank
ASST Martin Ratio Rank: 1616
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MLTX vs. ASST - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for MoonLake Immunotherapeutics (MLTX) and Asset Entities Inc. Class B Common Stock (ASST). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


MLTXASSTDifference
Sharpe ratioReturn per unit of total volatility

0.00

Sortino ratioReturn per unit of downside risk

+1.63

Omega ratioGain probability vs. loss probability

1.17

0.90

+0.27

Calmar ratioReturn relative to maximum drawdown

-0.70

-0.93

+0.24

Martin ratioReturn relative to average drawdown

-0.99

-1.15

+0.16

MLTX vs. ASST - Sharpe Ratio Comparison

The current MLTX Sharpe Ratio is -0.54, which is comparable to the ASST Sharpe Ratio of -0.54. The chart below compares the historical Sharpe Ratios of MLTX and ASST, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


MLTXASSTDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.54

-0.54

0.00

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.14

Sharpe Ratio (All Time)

Calculated using the full available price history

0.12

-0.19

+0.31

Drawdowns

MLTX vs. ASST - Drawdown Comparison

The maximum MLTX drawdown since its inception was -90.22%, smaller than the maximum ASST drawdown of -97.98%. Use the drawdown chart below to compare losses from any high point for MLTX and ASST.


Loading charts...

Drawdown Indicators


MLTXASSTDifference

Max Drawdown

Largest peak-to-trough decline

-90.22%

-97.98%

+7.76%

Max Drawdown (1Y)

Largest decline over 1 year

-89.93%

-95.98%

+6.05%

Max Drawdown (3Y)

Largest decline over 3 years

-90.22%

-97.25%

+7.03%

Max Drawdown (5Y)

Largest decline over 5 years

-90.22%

Current Drawdown

Current decline from peak

-71.39%

-95.85%

+24.46%

Average Drawdown

Average peak-to-trough decline

-29.15%

-84.09%

+54.94%

Ulcer Index

Depth and duration of drawdowns from previous peaks

62.80%

77.76%

-14.96%

Volatility

MLTX vs. ASST - Volatility Comparison

The current volatility for MoonLake Immunotherapeutics (MLTX) is 18.88%, while Asset Entities Inc. Class B Common Stock (ASST) has a volatility of 23.94%. This indicates that MLTX experiences smaller price fluctuations and is considered to be less risky than ASST based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


MLTXASSTDifference

Volatility (1M)

Calculated over the trailing 1-month period

18.88%

23.94%

-5.06%

Volatility (6M)

Calculated over the trailing 6-month period

56.83%

81.76%

-24.93%

Volatility (1Y)

Calculated over the trailing 1-year period

117.11%

165.43%

-48.32%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

91.12%

323.23%

-232.11%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

86.52%

323.23%

-236.71%

Dividends

MLTX vs. ASST - Dividend Comparison

Neither MLTX nor ASST has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

MLTX vs. ASST - Financials Comparison

This section allows you to compare key financial metrics between MoonLake Immunotherapeutics and Asset Entities Inc. Class B Common Stock. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00500.00K1.00M1.50M2.00M2.50M202220232024202520260
2.76M
(MLTX) Total Revenue
(ASST) Total Revenue
Values in USD except per share items

Frequently Asked Questions


MLTX and ASST have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ASST has higher volatility (23.94%) compared to MLTX (18.88%). In terms of maximum drawdown, MLTX dropped -90.22% vs ASST's -97.98%.

MLTX currently has the higher Sharpe Ratio (-0.54 vs -0.54), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for MLTX and ASST

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer